MHLW Approves Additional Indication For Taiho's Protecadin
This article was originally published in PharmAsia News
Executive Summary
Taiho Pharmaceutical received an additional indication approval in Japan for Protecadin (lafutidine) to treat reflux esophagitis. The approval was based on a Phase III study in which lafutidine demonstrated significant improvement in symptoms compared to placebo. Originally approved in 2000 for gastric ulcer, duodenal ulcer, acute and chronic gastritis, Protecadin achieved ¥7.5 billion in sales in 2009. (Click here for more - Japanese language)"Taiho Obtains Additional Indication Of Reflux Esophagitis For Protecadin" - CB News (3/15/2010)
You may also be interested in...
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.